Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13073268 | 0.82 | CYP19A1 (0.46) | CYP19A1NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL8101355 | 0.79 | CHRM2 (0.40) | SERPINE1CHRM2CHRM3CYP2D6 | |
| SCHEMBL1682649 | 0.78 | CYP19A1 (0.50) | CYP19A1NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL3676448 | 0.77 | CYP19A1 (0.36) | CYP19A1NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL3678287 | 0.77 | CYP19A1 (0.36) | CYP19A1NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL28317353 | 0.77 | CYP19A1 (0.53) | CYP19A1NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL2182130 | 0.77 | CYP19A1 (0.53) | CYP19A1NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL8101351 | 0.76 | SERPINE1 (0.35) | SERPINE1 | |
| SCHEMBL8097054 | 0.75 | CHRM2 (0.44) | CYP19A1SERPINE1HTTSMN1; SMN2CHRM2 | |
| SCHEMBL8097050 | 0.75 | SERPINE1 (0.33) | SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781599-B2 | economical; nontoxic; high yield; industrial scale; Grignard reaction; iron catalyst (FeCl3) and a diamine (ethylenediamine); cross-coupling of alkyl halide and aromatic organometallic; primary or secondary alkyl substituents; phenylcycloheptane from bromocycloheptane and phenyl magnesium bromide | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781599-B2 | economical; nontoxic; high yield; industrial scale; Grignard reaction; iron catalyst (FeCl3) and a diamine (ethylenediamine); cross-coupling of alkyl halide and aromatic organometallic; primary or secondary alkyl substituents; phenylcycloheptane from bromocycloheptane and phenyl magnesium bromide | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20070123734-A1 | Process for production of aromatic compounds | JAPAN SCIENCE AND TECHNOLOGY AGENCY | 2007-05-31 | — | — | US | disclosed |
| US-20070123734-A1 | Process for production of aromatic compounds | JAPAN SCIENCE AND TECHNOLOGY AGENCY | 2007-05-31 | — | — | US | disclosed |
| EP-1724248-A1 | PROCESS FOR PRODUCTION OF AROMATIC COMPOUNDS | Japan Science and Technology Agency (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123734-A1 | Process for production of aromatic compounds | C9, C5, C1S | CYP19A1 140/4885SERPINE1 3877/4885NPC1 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.